Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly and Company to apply the AbiProt® technology to generate antibodies to a high-value target

The parties already have an existing agreement in place (signed in November 2023) and this agreement expands the collaboration between the companies to a second high-value target. The parties already have an existing agreement in place (signed inNovember 2023 ) and this agreement expands the collaboration between the companies to a second high-value target. " We are delighted to expand the collaboration between our companies and together create new science to address the unmet medical need...

The parties already have an existing agreement in place (signed in November 2023) and this agreement expands the collaboration between the companies to a second high-value target.

"We are delighted to expand the collaboration between our companies and together create new science to address the unmet medical need in severe diseases. This collaboration with Lilly is of great importance to us and will further strengthen our position within the antibody discovery space," says Christer Nordstedt, CEO at Oblique Therapeutics.

About Oblique Therapeutics

Oblique Therapeutics is a biotechnology company that focuses on developing new therapeutic methods for treating severe illnesses, especially in the area of pain management and also for other conditions. The company uses pioneering technology and innovative research methods to discover and develop new antibody-based drug candidates.

Contact: Christer Nordstedt ([email protected])

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/oblique-therapeutics-ab/r/oblique-therapeutics-has-entered-a-research-collaboration-agreement-with-eli-lilly-and-company-to-ap,c4027460

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/oblique-therapeutics-has-entered-a-research-collaboration-agreement-with-eli-lilly-and-company-to-apply-the-abiprot-technology-to-generate-antibodies-to-a-high-value-target-302228552.html